Infect Immun 1993,61(11):4870–4877.PubMed 33. Ng TT, Robson GD, Denning DW: Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 1994,140(Pt 9):2475–2479.PubMedCrossRef 34. Swords FM, Carroll PV, Kisalu J, Wood PJ, Taylor NF, Monson JP: The effects of growth hormone deficiency and replacement on glucocorticoid

exposure in hypopituitary patients on cortisone acetate and hydrocortisone replacement. Clin Endocrinol (Oxf) 2003,59(5):613–620.CrossRef SCH727965 concentration 35. Mehrad B, Moore TA, Standiford TJ: Macrophage inflammatory protein-1 alpha is a critical mediator of host defense against invasive pulmonary aspergillosis in neutropenic hosts. J Immunol 2000,165(2):962–968.PubMed 36. Bonnett CR, Cornish EJ, Harmsen AG, Burritt JB: Early neutrophil recruitment and aggregation in Nepicastat manufacturer the murine lung inhibit germination of Aspergillus fumigatus Conidia. Infect Immun 2006,74(12):6528–6539.PubMedCrossRef 37. Kaneko M, Kawakita T, Kumazawa Y, Takimoto H, Nomoto K, Yoshikawa T: Accelerated recovery from cyclophosphamide-induced leukopenia in mice administered a Japanese ethical herbal drug, Hochu-ekki-to. Immunopharmacology 1999,44(3):223–231.PubMedCrossRef 38. Hirsh M, Carmel J, Kaplan V, Livne

E, Krausz MM: Activity of lung neutrophils and matrix metalloproteinases in mafosfamide cyclophosphamide-treated mice with experimental sepsis. Int J Exp VX-809 in vivo Pathol 2004,85(3):147–157.PubMedCrossRef 39.

Montillo M, Tedeschi A, O’Brien S, Di Raimondo F, Lerner S, Ferrajoli A, Morra E, Keating MJ: Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 2003,97(1):114–120.PubMedCrossRef 40. Calame W, Douwes-Idema AE, Barselaar MT, Mattie H: Contribution of alveolar phagocytes to antibiotic efficacy in an experimental lung infection with Streptococcus pneumoniae. J Infect 2001,42(4):235–242.PubMedCrossRef 41. Gadeberg OV, Rhodes JM, Larsen SO: The effect of various immunosuppressive agents on mouse peritoneal macrophages and on the in vitro phagocytosis of Escherichia coli O4:K3:H5 and degradation of 125I-labelled HSA-antibody complexes by these cells. Immunology 1975,28(1):59–70.PubMed 42. Muruganandan S, Lal J, Gupta PK: Immunotherapeutic effects of mangiferin mediated by the inhibition of oxidative stress to activated lymphocytes, neutrophils and macrophages. Toxicology 2005,215(1–2):57–68.PubMedCrossRef 43. Kaufmann SH, Hahn H, Diamantstein T: Relative susceptibilities of T cell subsets involved in delayed-type hypersensitivity to sheep red blood cells to the in vitro action of 4-hydroperoxycyclophosphamide. J Immunol 1980,125(3):1104–1108.PubMed 44.